ClinicalTrials.gg
Active, not recruitingNCT02835950TROPHY 1-USUpdated Aug 21, 2023

TReatment Of Pulmonary HYpertension 1-US Study

An interventional study of Therapeutic Intra-Vascular UltraSound (TIVUS™) System in Pulmonary Arterial Hypertension, sponsored by SoniVie Inc.. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.

Sponsored by SoniVie Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Planned enrollment
190th of 253
15 · median 40
Started
2017
with 14 others
No phase
26 of 313
4 open now
Primary completion
2019-04
later than 1 of 55 live
Registered
168th of 313
by date

Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 190th largest by planned enrollment of the 253 interventional ones that give a count, is one of 15 that started in 2017, is one of 26 with no phase, reaches primary completion later than 1 of the 55 other live ones, and was the 168th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and haemodynamic evaluation. This is a prospective, multi-center, non-randomized, open-label clinical trail. The study will be conducted in up to 4 centers and will recruit up to 15 patients diagnosed with PAH, functional class III who have stable PAH on a stable drug regimen of two pulmonary arterial hypertension specific medications.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with known pulmonary arterial hypertension (PAH), diagnosed as idiopathic PAH, connective tissue disease PAH, Anorexogen induced or Heritable PAH
  • PAH diagnosis confirmed by hemodynamic evaluation performed prior to screening and showing all of the following: Mean pulmonary artery pressure (mPAP) ≥25 mmHg at rest; Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤15 mmHg; Pulmonary vascular resistance (PVR) at rest >3 Wood units; Not meeting the criteria for a positive vasodilator response (fall in mPAP ≥ 10 mmHg to ≤ 40 mmHg).
  • Patient with a current diagnosis of WHO functional class III
  • Patient taking two pulmonary arterial hypertension specific medications other than parenteral prostanoids
  • Patient is adhering to a stable drug regimen (i.e., with no changes of dose or medication for a minimum of 3 months prior to enrollment)
  • Patient with levels of ≥ 30 ml/min/1.73m2or serum creatinine levels of ˂ 150µmol/l

Exclusion criteria

Exclusion Criteria:

  • Patients who are treated with parenteral prostanoids
  • Pregnant women or women planning a pregnancy within 12 months of study enrolment
  • Patient with significant co-morbid condition(s) which, at the discretion of the PI, are deemed to prohibit study entry
  • Patient with of less than a year
  • Concurrent enrollment in another device or drug trial except for observational studies (unless specifically approved by the sponsor)
  • Patient with pulmonary artery anatomy that precludes treatment
  • Patient with moderate to severe pulmonary artery stenosis
  • Patient with any pulmonary artery aneurysm
  • Patient who has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident in the previous 6 months
  • Patient who has implantable cardiac pacemakers, ICDs, neurostimulators, or drug infusion devices
  • Patients who are unable to undergo an MRI scan
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Pulmonary Denervation

    Pulmonary Denervation (PDN) using the TIVUS™ System will be performed in patient suffering from pulmonary arterial hypertension after completion of screening and eligibility phase, The procedure will be performed during right heart catheterisation. Safety and effectiveness of the PDN treatment will be assessed during one year follow up.

    Device: Therapeutic Intra-Vascular UltraSound (TIVUS™) System

Interventions

  • DeviceTherapeutic Intra-Vascular UltraSound (TIVUS™) System

    The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation. Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation.

    Also known as: TIVUS™

06

What researchers measure

Primary outcomes

  1. Amount of all procedural related adverse event as assessed by the CEC

    Procedural related Adverse Events

    Time frame: 1 month

  2. Amount of treatment related adverse event as assessed by the CEC

    All treatment related adverse events

    Time frame: 12 month

  3. Number of patient with PAH worsening and all cause death events

    PAH related adverse events and all cause death

    Time frame: 12 month

Secondary outcomes

  1. Clinical effectiveness

    Changes from baseline of mean pulmonary arterial pressure (mPAP)

    Time frame: 6 months

  2. Clinical effectiveness

    Changes from baseline of pulmonary vascular resistance (PVR)

    Time frame: 6 months

  3. Clinical effectiveness

    Changes from baseline of 6 minute walking distance (6MWD)

    Time frame: 6 months

  4. Clinical effectiveness

    Changes from baseline of quality of life questionaire

    Time frame: 6 months

  5. Clinical effectiveness

    NT-pro-BNP levels

    Time frame: 1, 6 and 12 months

  6. Clinical efffectivness

    Change from baseline in Right Ventricular (RV) function as assesed by MRI

    Time frame: 6 months

  7. Clinical efffectivness

    Change from baseline in Right Ventricular (RV) function as assesed by Echocardiography

    Time frame: 6 months

Other outcomes

  1. Observational Variables

    Changes from baseline of mean pulmonary arterial pressure (mPAP)

    Time frame: 12 Months

  2. Observational Variables

    Changes from baseline of pulmonary vascular resistance (PVR)

    Time frame: 12 Months

  3. Observational Variables

    Changes from baseline of 6 minute walking distance (6MWD)

    Time frame: 12 Months

  4. Observational Variables

    Changes from baseline of quality of life questionaire

    Time frame: 12 Months

  5. Observational Variables - Long term surveillance

    Clinical change of pulmonary arterial hypertension condition defined by patient survival or cause of mortality

    Time frame: 2, 3, 4 and 5 years

  6. Observational Variables - Long term surveillance

    Clinical change of pulmonary arterial hypertension condition defined by hospitalization due to pulmonary arterial hypertension

    Time frame: 2, 3, 4 and 5 years

  7. Observational Variables - Long term surveillance

    Clinical change of pulmonary arterial hypertension condition defined by any intervention or surgical procedures the patient did

    Time frame: 2, 3, 4 and 5 years

  8. Observational Variables - Long term surveillance

    Clinical change of pulmonary arterial hypertension condition defined by worsening of WHO functional class

    Time frame: 2, 3, 4 and 5 years

  9. Observational Variables - Long term surveillance

    Clinical change of pulmonary arterial hypertension condition defined by escalation of drug therapy

    Time frame: 2, 3, 4 and 5 years

  10. Observational Variables

    Echocardiography parameters

    Time frame: 12 month

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Apr 2019, 25 months.

Of 65 interventional studies with no phase under Pulmonary Arterial Hypertension, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2016
First posted
Jul 18, 2016
StartActual
Mar 1, 2017
Primary completionActual
Apr 20, 2019
CompletionEst.
Dec 2023
Last update
Aug 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02835950
Lead sponsor
SoniVie Inc.
Responsible party
Sponsor
First posted
Jul 18, 2016
Start date
Mar 1, 2017
Primary completion
Apr 20, 2019
Completion
Dec 2023 (estimated)
Last update
Aug 21, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion